Please login to the form below

Not currently logged in

Pfizer expands generic portfolio

Pfizer has entered into a series of agreements to commercialise several products that have lost market exclusivity in the US and Europe

Pfizer has entered into a series of agreements with India-based, Aurobindo to commercialise several products that have lost market exclusivity in the US and Europe.

The commercialisation will be managed by Pfizer's Established Product Business Unit, which has global annual sales of $10bn. The financial terms of the deal have not been disclosed.

The agreement relates to solid oral dose medicines that are no longer protected by patents and includes 39 products in the US, 20 in Europe including a further 11 in France, covering a broad range of therapeutic areas such as central nervous system disorders and cardiovascular disease. In addition, Pfizer has acquired the rights to 12 sterile injectable antibiotic products in the US and Europe.

"We will dramatically change Pfizer's Established Products portfolio to an engine of positive growth. These agreements represent solid, measurable progress, and a strong commitment to achieve our growth objectives," said David Simmons, president and general manager of Pfizer's Established Products Business Unit.

These agreements build on a five-product US deal agreed between the companies in July 2008.

4th March 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...